Capital Analysts LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Analysts LLC’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$202	Buy	+10	New	+$268	﹤0.01%	1687

Other funds holding ACAD

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Capital Analysts LLC's ACAD Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 10 shares worth $202. The stake represents ﹤0.01% of the portfolio and ranks #1687 among its holdings.

263 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Capital Analysts LLC held 10 shares of Acadia Pharmaceuticals worth $202 as of Q3 2026.
Acadia Pharmaceuticals was a new Capital Analysts LLC position in Q3 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #1687 holding.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.